Multiple drugs improve the activity of remdesivir, a current standard-of-care treatment for COVID-19
A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.
Sumit Chanda, Ph.D., director and professor of Sanford Burnham Prebys’ Immunity and Pathogenesis Program and senior author of the bioRxiv study that identifies potential near-term COVID-19 treatments
Sumit Chanda, Ph.D., director and professor of Sanford Burnham Prebys’ Immunity and Pathogenesis Program and senior author of the Nature study that identifies 21 potential near-term COVID-19 treatments.
The scientists analyzed one of the world’s largest collections of known drugs for their ability to block the replication of SARS-CoV-2, and reported 100 molecules with confirmed antiviral activity in laboratory tests. Of these, 21 drugs were determined to be effective at concentrations that could be safely achieved in patients. Notably, four of these compounds were found to work synergistically with remdesivir, a current standard-of-care treatment for COVID-19.
